[1] |
Chrystoja, B.R.; Rehm, J.; Manthey, J.; Probst, C.; Wettlaufer, A.; Shield, K.D. A systematic comparison of the global comparative risk assessments for alcohol. Addiction. 2021, 116, 2026–2038.
|
[2] |
Haber, P.S.; Kortt, N.C. Alcohol use disorder and the gut. Addiction. 2021, 116, 658–667.
|
[3] |
Wang, X.; He, Y.; Mackowiak, B.; Gao, B. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut. 2021, 70, 784–795.
|
[4] |
Stornetta, A.; Guidolin, V.; Balbo, S. Alcohol-derived acetaldehyde exposure in the oral cavity. Cancers. 2018, 10. DOI:10.3390/cancers10010020.
|
[5] |
Dunn, W.; Shah, V.H. Pathogenesis of alcoholic liver disease. Clin. Liver Dis. 2016, 20, 445–456.
|
[6] |
Smyth, A.; Teo, K.K.; Rangarajan, S.; O'Donnell, M.; Zhang, X.H.; Rana, P.; Leong, D.P.; Dagenais, G.; Seron, P.; Rosengren, A.; Schutte, A.E.; Lopez-Jaramillo, P.; Oguz, A.; Chifamba, J.; Diaz, R.; Lear, S.; Avezum, A.; Kumar, R.; Yusuf, S. Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study. Lancet. 2015, 386, 1945–1954.
|
[7] |
Xi, B.; Veeranki, S.P.; Zhao, M.; Ma, C.W.; Yan, Y.K.; Mi, J. Relationship of alcohol consumption to all-cause, cardiovascular, and cancer-related mortality in US adults. J. Am. Coll. Cardiol. 2017, 70, 913–922.
|
[8] |
Duddempudi, A.T. Immunology in alcoholic liver disease. Clin. Liver Dis. 2012, 16, 687–698.
|
[9] |
Li, M.; He, Y.; Zhou, Z.; Ramirez, T.; Gao, Y.Q.; Gao, Y.H.; Ross, R.A.; Cao, H.X.; Cai, Y.; Xu, M.J.; Feng, D.C.; Zhang, P.; Liangpunsakul, S.; Gao, B. MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6–p47phox–oxidative stress pathway in neutrophils. Gut. 2017, 66, 705–715.
|
[10] |
Acito, M.; Bartolini, D.; Ceccarini, M.R.; Russo, C.; Vannini, S.; Dominici, L.; Codini, M.; Villarini, M.; Galli, F.; Beccari, T.; Moretti, M. Imbalance in the antioxidant defence system and pro-genotoxic status induced by high glucose concentrations: In vitro testing in human liver cells. Toxicol. Vitro. 2020, 69, 105001.
|
[11] |
Mahmoud, A.M.; Hussein, O.E.; Hozayen, W.G.; Bin-Jumah, M.; Abd El-Twab, S.M. Ferulic acid prevents oxidative stress, inflammation, and liver injury via upregulation of Nrf2/HO-1 signaling in methotrexate-induced rats. Environ. Sci. Pollut. Res. 2020, 27, 7910–7921.
|
[12] |
Grabherr, F.; Grander, C.; Adolph, T.E.; Wieser, V.; Mayr, L.; Enrich, B.; Macheiner, S.; Sangineto, M.; Reiter, A.; Viveiros, A.; Zoller, H.; Bufler, P.; Moschen, A.R.; Dinarello, C.A.; Tilg, H. Ethanol-mediated suppression of IL-37 licenses alcoholic liver disease. Liver Int. 2018, 38, 1095–1101.
|
[13] |
Tilg, H.; Moschen, A.R.; Szabo, G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2016, 64, 955–965.
|
[14] |
Mukhopadhyay, P.; Horváth, B.; Rajesh, M.; Varga, Z.V.; Gariani, K.; Ryu, D.; Cao, Z.X.; Holovac, E.; Park, O.; Zhou, Z.; Xu, M.J.; Wang, W.; Godlewski, G.; Paloczi, J.; Nemeth, B.T.; Persidsky, Y.; Liaudet, L.; Haskó, G.; Pacher, P. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis. J. Hepatol. 2017, 66, 589–600.
|
[15] |
Zhou, Y.; Yuan, G.D.; Zhong, F.D.; He, S.Q. Roles of the complement system in alcohol-induced liver disease. Clin. Mol. Hepatol. 2020, 26, 677–685.
|
[16] |
Zhang, M.; Zhang, Y.; Liu, L.; Prithweeraj, M.; Xu, H.; Wu, R.; Wen, X.; Niu, J. Neutrophil-to-lymphocyte ratio and albumin: new serum biomarkers to predict the prognosis of male alcoholic cirrhosis patients. Biomed. Res. Int. 2020, 2020, 7268459.
|
[17] |
Tang, Y.M.; Banan, A.; Forsyth, C.B.; Fields, J.Z.; Lau, C.K.; Zhang, L.J.; Keshavarzian, A. Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. Alcohol. Clin. Exp. Res. 2008, 32, 355–364.
|
[18] |
Affò, S.; Morales-Ibanez, O.; Rodrigo-Torres, D.; Altamirano, J.; Blaya, D.; Dapito, D.H.; Millán, C.; Coll, M.; Caviglia, J.M.; Arroyo, V.; Caballería, J.; Schwabe, R.F.; Ginès, P.; Bataller, R.; Sancho-Bru, P. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut. 2014, 63, 1782–1792.
|
[19] |
Liang, S.; Zhong, Z.Y.; Kim, S.Y.; Uchiyama, R.; Roh, Y.S.; Matsushita, H.; Gottlieb, R.A.; Seki, E. Murine macrophage autophagy protects against alcohol-induced liver injury by degrading interferon regulatory factor 1 (IRF1) and removing damaged mitochondria. J. Biol. Chem. 2019, 294, 12359–12369.
|
[20] |
Zhang, L.; Pan, JC.; Ku, BS. Protective Effect of Ascorbate-Lysine on Carbon Tetrachloride and Alcohol-Induced Liver Injury in Mice. J. Chin. Pharm. Sci. 2004, 4, 288–290.
|
[21] |
Huo, X.W.; Sun, X.K.; Cao, Z.P.; Qiao, J.Z.; Yang, S.; Meng, X.B.; Zhao, Y.Y. Optimal ratio of 18α- and 18β-glycyrrhizic acid for preventing alcoholic hepatitis in rats. Exp. Ther. Med. 2019, 18, 172–178.
|
[22] |
Song, Z.Y.; Deaciuc, I.; Song, M.; Lee, D.Y.W.; Liu, Y.Z.; Ji, X.S.; McClain, C. Silymarin protects against acute ethanol-induced hepatotoxicity in mice. Alcohol. Clin. Exp. Res. 2006, 30, 407–413.
|
[23] |
Addolorato, G.; Ancona, C.; Capristo, E.; Gasbarrini, G. Metadoxine in the treatment of acute and chronic alcoholism: a review. Int. J. Immunopathol. Pharmacol. 2003, 16, 207–214.
|
[24] |
Díaz Martínez, M.C.; Díaz Martínez, A.; Villamil Salcedo, V.; Cruz Fuentes, C. Efficacy of metadoxine in the management of acute alcohol intoxication. J. Int. Med. Res. 2002, 30, 44–51.
|
[25] |
Tijera, F.H.D.L.; Servín-Caamaño, A.I.; Cruz-Herrera, J.; Serralde-Zúñiga, A.E.; Abdo-Francis, J.M.; Gutiérrez-Reyes, G.; Pérez-Hernández, J.L. Treatment with Metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Ann. Hepatol. 2014, 13, 343–352.
|
[26] |
Testino, G.; Leone, S.; Fagoonee, S.; Pellicano, R. Alcoholic liver fibrosis: detection and treatment. Minerva Med. 2018, 109, 457–471.
|
[27] |
Mazraati, P.; Minaiyan, M. Hepatoprotective effect of metadoxine on acetaminophen-induced liver toxicity in mice. Adv. Biomed. Res. 2018, 7, 67.
|
[28] |
Gutiérrez-Ruiz, M.C.; Bucio, L.; Correa, A.; Souza, V.; Hernández, E.; Gómez-Quiroz, L.E.; Kershenobich, D. Metadoxine prevents damage produced by ethanol and acetaldehyde in hepatocyte and hepatic stellate cells in culture. Pharmacol. Res. 2001, 44, 431–436.
|
[29] |
Wu, J.D.; Wu, D.Q.; Ma, K.L.; Wang, T.M.; Shi, G.X.; Shao, J.; Wang, C.Z.; Yan, G.M. Paeonol ameliorates murine alcohol liver disease via mycobiota-mediated Dectin-1/IL-1β signaling pathway. J. Leukoc. Biol. 2020, 108, 199–214.
|
[30] |
Gu, G.X.; Huo, Y.F.; Xu, G.; Li, L.M.; Yu, J.; Sheng, L.X.; Yin, Z.Y. MicroRNA-204-GSDMD interaction regulates pyroptosis of fibroblast-like synoviocytes in ankylosing spondylitis. Int. Immunopharmacol. 2021, 91, 107227.
|
[31] |
Xi, H.; Zhang, Y.; Xu, Y.; Yang, W.Y.; Jiang, X.; Sha, X.; Cheng, X.; Wang, J.; Qin, X.; Yu, J.; Ji, Y.; Yang, X.; Wang, H. Caspase-1 inflammasome activation mediates homocysteine-induced pyrop-apoptosis in endothelial cells. Circ. Res. 2016, 118, 1525–1539.
|
[32] |
Ding, W.X.; Manley, S.; Ni, H.M. The emerging role of autophagy in alcoholic liver disease. Exp. Biol. Med. (Maywood). 2011, 236, 546–556.
|
[33] |
Ding, W.X.; Li, M.; Chen, X.Y.; Ni, H.M.; Lin, C.W.; Gao, W.T.; Lu, B.F.; Stolz, D.B.; Clemens, D.L.; Yin, X.M. Autophagy reduces acute ethanol-induced hepatotoxicity and steatosis in mice. Gastroenterology. 2010, 139, 1740–1752.
|
[34] |
Wang, H.F.; Huang, J.; Zhang, S.; Jia, B.; Yang, D.W. Effect and mechanisms of the metadoxin attenuates steatosis in cultured hepatic cells by inducing autophagy. Chin. J. Clin. Pharmacol. 2019, 35, 1752–1755.
|